Warfarin Sodium Tablets

DRUG4 trials

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., Guangdong Raynovent Biotech Co., Ltd

Conditions

Chronic Hepatitis BHealthy SubjectsObesityRheumatoid Arthritis

Phase 1

A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects

CompletedNCT05045313

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Healthy Subjects

Start: 2021-10-20End: 2021-12-01Updated: 2022-03-10

A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers

CompletedNCT05273775

Jiangsu HengRui Medicine Co., Ltd.Chronic Hepatitis B

Start: 2022-04-29End: 2022-06-23Updated: 2022-12-23

A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers

CompletedNCT05392127

Jiangsu HengRui Medicine Co., Ltd.Rheumatoid Arthritis

Start: 2022-07-15End: 2022-08-18Updated: 2022-12-22

Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin

Active, not recruitingNCT07362030

Guangdong Raynovent Biotech Co., LtdObesity

Start: 2025-04-14End: 2026-03-30Updated: 2026-01-23

Related Papers

Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis

British Journal of Clinical Pharmacology2023-07-191 citations